Legal Labels!

Last week the Supreme Court shielded makers of generic drugs from suit as long as their labels follow the brand-name (BN) counterpart. As a result consumers harmed by inadequate warnings can obtain relief only if they purchase BN drugs. The good news: generics will get cheaper as fear of lawsuits is reduced. The bad news: generic manufacturers will no longer be required to monitor their product’s safety.

Share This Post
Facebook Twitter Email

Speak Your Mind


This site uses Akismet to reduce spam. Learn how your comment data is processed.